Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Allogene Therapeutics Inc
(NQ:
ALLO
)
2.230
-0.070 (-3.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allogene Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Analyst Ratings For Allogene Therapeutics
May 31, 2024
Via
Benzinga
If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names
May 28, 2024
Penny stocks to buy carry a great deal of risk. However, there are a few that look interesting after due diligence.
Via
InvestorPlace
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
May 23, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
May 21, 2024
Via
Benzinga
Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views
May 15, 2024
Via
Benzinga
Recap: Allogene Therapeutics Q4 Earnings
March 14, 2024
Via
Benzinga
Allogene Therapeutics Earnings Preview
March 13, 2024
Via
Benzinga
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 21, 2024
Via
Benzinga
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
May 15, 2024
Via
Benzinga
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
May 15, 2024
Via
Benzinga
ALLO Stock Earnings: Allogene Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 13, 2024
ALLO stock results show that Allogene Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
May 13, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
May 13, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
May 06, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 06, 2024
Via
Benzinga
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
April 26, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
April 18, 2024
Via
Benzinga
Topics
ETFs
3 Meme Stocks to Sell and Replace With Meme Coins
April 11, 2024
For investors who want to avoid losses, sell or avoid certain meme stocks that are on the radar for potential sell-offs.
Via
InvestorPlace
Allogene Therapeutics Announces Q2 Investor Conference Participation
April 09, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
ALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023
March 14, 2024
ALLO stock results show that Allogene Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
March 14, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 14, 2024
March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.
Via
Benzinga
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
March 12, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
March 05, 2024
Conference Call and Webcast Scheduled for March 14, 2024 at 2:00 p.m. PT/5:00 p.m. ET
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
February 28, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
February 16, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
February 12, 2024
U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
January 16, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Cell Therapy Focused Allogene Therapeutics' Resource Prioritization A Bold Move, Says Analyst
January 05, 2024
Allogene Therapeutics Inc (NASDAQ: ALLO) announced deprioritizing the currently enrolling third line Phase 2 ALPHA2 and EXPAND trials of cema-cel (ALLO-501A) and is now pursuing a potentially pivotal...
Via
Benzinga
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 05, 2024
Shares of Applied Therapeutics, Inc.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.